Healx Platform
AI-powered drug discovery platform for rare diseases
Platform · OtherCompany source
Company profile
About Healx
Healx is a biotechnology company pioneering the use of artificial intelligence to accelerate drug discovery for rare diseases. Founded with the mission to bring treatments to the 95% of rare diseases that currently have no approved therapies, Healx has developed a proprietary AI-driven platform that combines machine learning algorithms with diverse biomedical data sources to identify promising drug candidates. The company's approach focuses on drug repurposing, leveraging existing compounds to reduce development timelines and costs while improving the probability of success. Healx's technology platform integrates multiple data types including genomic information, clinical data, scientific literature, and molecular databases to generate novel insights into disease mechanisms and potential therapeutic interventions. By applying advanced computational methods to rare disease research, Healx aims to transform the drug development landscape for underserved patient populations. The company works with pharmaceutical partners, patient advocacy groups, and research institutions to advance its pipeline of rare disease treatments from discovery through clinical development.
Company description Healx official website
Primary marketDrug Discovery & Development
Commercial modelCommercial information available on request
Company presenceLinkedIn
Work at Healx?
Claim this listing Claim this profile to manage Company information and connect with the Health AI Central audience.
01 · Operating footprint
Where the Company operates
Company-profile context for clinical focus, customers, deployment, integration, milestones, and partnerships.
Clinical focus
- rare diseases
Who it serves
- Pharma
Deployment & integration
Other deployment with recorded integration context.
Geographic context
MarketsNot currently listed
Company sourceOfficial website
02 · Flagship portfolio
Products, workflows, and platform capabilities
Selected source-backed Company products and the available commercial context.
03 · Research intelligence
Research Intelligence evidence
Publications, preprints, clinical validation, and regulatory records in Evidence Position order.
Evidence position
Publications, clinical validation, and regulatory records connected to this Company appear here.
Research
Publications & preprints
Gaboxadol increases resting theta and alpha power without affecting evoked responses in fragile X syndrome in a home-based setting.Journal of neurodevelopmental disorders · May 8, 2026
Repurposing statins and phenothiazines to treat chemoresistant neuroblastoma.EMBO molecular medicine · Feb 1, 2026
IntAct Database for Accessing IMEx's Contextual Metadata of Molecular Interactions.Current protocols · Oct 1, 2024
An experimentally validated approach to automated biological evidence generation in drug discovery using knowledge graphs.Nature communications · Jul 8, 2024
A novel combination treatment for fragile X syndrome predicted using computational methods.Brain communications · Jan 1, 2024
Computational drug discovery approaches identify mebendazole as a candidate treatment for autosomal dominant polycystic kidney disease.Frontiers in pharmacology · Jan 1, 2024
Clinical validation
Clinical-trial records
Domatinostat With Sirolimus for Relapsed, Refractory Sarcoma and OsteosarcomaNCT07725380 · Sponsor · RECRUITING
A Phase 2, Open-Label Study to Evaluate the Safety and Effects of HLX-1502 in Patients With Neurofibromatosis Type 1NCT06541847 · Sponsor · RECRUITING
Placebo-Controlled, Single-Dose Challenge Study of Gaboxadol in Adult Males With Fragile X Syndrome (FXS)NCT06334419 · Sponsor · COMPLETED
A Study in Adults and Adolescents With Angelman Syndrome (STARS)NCT02996305 · Sponsor · COMPLETED
An Open-Label Study to Evaluate the Long-Term Safety, Tolerability, and Efficacy of OV101 in Individuals With Angelman SyndromeNCT03882918 · Sponsor · TERMINATED
A Study of OV101 in Individuals With Fragile X SyndromeNCT03697161 · Sponsor · COMPLETED
Regulatory
Regulatory records
No linked records are currently available.
04 · Company-reported outcomes
Outcomes and case studies
Company-reported outcomes and customer stories are distinct from linked Research Intelligence evidence.
No Company-reported outcomes are currently listed.
05 · Leadership
Leadership team
Leadership profiles and professional links from the current Company record.
No active leadership profiles are currently listed.
06 · Company updates
Updates from Healx
Recent articles published on Healx's official website.
No Company updates are currently listed.
07 · HAIC coverage
Coverage and analysis
Health AI Central reporting that mentions this Company.
No HAIC coverage is currently linked to this Company.
08 · Official presence
Company sources and channels
Curated official destinations from the active Company record.
09 · Market pathway
Additional Companies in this Market
Other active Companies in the same market, selected alphabetically from the HAIC directory.
Market context
Drug Discovery & Development
Companies using AI, machine learning, or computational biology to discover new drug candidates, identify drug targets, predict drug efficacy, or accelerate pharmaceutical development. Includes both small molecule and biologics development, precision oncology drug discovery, and AI-driven target identification and molecule design.
Explore the full market directory or compare this Company with additional active profiles.
View all Companies in this market
10 · Pro research
Coming soon
Expanded Company research is in development.
Health AI Central Pro · Coming Soon
Deeper Company research is coming soon.
Pro Research will introduce expanded technical context, linked evidence analysis, and comparative Company research.
Linked research, clinical, and regulatory source pathways.
Expanded product, deployment, integration, and partnership research.
Record-level provenance and review context.